<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04914897</url>
  </required_header>
  <id_info>
    <org_study_id>ACT16849</org_study_id>
    <secondary_id>U1111-1254-0107</secondary_id>
    <secondary_id>2020-005331-78</secondary_id>
    <secondary_id>Merck MK3475-B71</secondary_id>
    <nct_id>NCT04914897</nct_id>
  </id_info>
  <brief_title>A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma</brief_title>
  <official_title>A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To determine the antitumor activity of SAR444245 in combination with other anticancer&#xD;
      therapies.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To confirm the dose and to assess the safety profile of SAR444245 when combined with&#xD;
           other anticancer therapies.&#xD;
&#xD;
        -  To assess other indicators of antitumor activity.&#xD;
&#xD;
        -  To assess the pharmacokinetic (PK) profile of SAR444245 when given in combination with&#xD;
           pembrolizumab.&#xD;
&#xD;
        -  To assess the immunogenicity of SAR444245.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duration of Study: Up to 6 years (screening period [28 days], treatment period [max 35 cycles&#xD;
      = 735 days] and follow-up period [approximately 3 years])&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 21, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximatively 9 months after the last participant receive first dose.</time_frame>
    <description>Objective response rate (ORR), defined as the proportion of participants who have a confirmed complete response (CR) or partial response (PR), derived based on Investigator's assessment per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for Cohort A1, Cohort A2, Cohort A3, Cohort B1 and Cohort B2; per modified RECIST (mRECIST) for Cohort C1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To confirm the dose</measure>
    <time_frame>Observation period is 1 cycle (21 days)</time_frame>
    <description>Incidence of Dose-limiting toxicities (DLTs) during DLT observation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of SAR444245 safety profile when combined with other anticancer therapies-Treatment Emergent Adverse Events</measure>
    <time_frame>From 1st IMP dose up to 30 days after the last dose of IMP</time_frame>
    <description>Incidence of Treatment Emergent Adverse Events (TEAEs) and laboratory abnormalities according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus gradings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of SAR444245 safety profile when combined with other anticancer therapies-Serious Adverse Events</measure>
    <time_frame>From 1st IMP dose up to 90 days after the last dose of IMP</time_frame>
    <description>Incidence of Serious Adverse Events (SAEs) and laboratory abnormalities according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus gradings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>From the date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>Time to response defined as the time from the first administration of IMP to the first documented evidence of PR (partial response) or CR (complete response) per RECIST 1.1 (for NSCLC) or mRECIST (for mesothelioma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From the date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>Duration of response (DoR), defined as the time from first documented evidence of CR or PR until progressive disease (PD) determined per RECIST 1.1 (for NSCLC) or mRECIST (for mesothelioma) or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>From the date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>Clinical benefit rate (CBR) including CR or PR at any time plus stable disease (SD) of at least 6 months (per RECIST 1.1 [for NSCLC] or mRECIST [for mesothelioma]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From the date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>Progression free survival (PFS), defined as the time from the date of first IMP administration to the date of the first documented disease progression as per RECIST 1.1 for NSCLC) or mRECIST (for mesothelioma) or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the plasma concentrations of SAR444245</measure>
    <time_frame>At Day1 and Day 15 of Cycle1, at Day 1 of Cycle 2-4-7-10 + every 5th cycle (each cycle is 21 days), maximum is up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the incidence of anti-drug antibodies (ADAs) against SAR444245.</measure>
    <time_frame>At Day1 and Day 15 of Cycle1, at Day 1 of Cycle 2-4-7-10 + every 5th cycle (each cycle is 21 days) and 30 days after last IMP administration, maximum is up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Pleural Mesothelioma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A1: SAR444245 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2: SAR444245 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3: SAR444245 + pembrolizumab + pemetrexed + carboplatin/cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR444245 + pembrolizumab on day 1 of a 21 day treatment cycle (up to 35 cycles) Carboplatin/cisplatin on day 1 of a 21-day treatment cycle (up to 4 cycles) Pemetrexed on day 1 of a 21-day treatment cycle (until progressive disease or intolerability)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1: SAR444245 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2: patients with NSCLC, to receive SAR444245+pembrolizumab+nab paclitaxel as 2/3L therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR444245 + pembrolizumab (up to 35 cycles), and nab-paclitaxel (up to 6 cycles) on day 1 of a 21-day treatment cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C1: SAR444245 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR444245</intervention_name>
    <description>Pharmaceutical Form: Solution for infusion Route of Administration: intravenous infusion</description>
    <arm_group_label>Cohort A1: SAR444245 + pembrolizumab</arm_group_label>
    <arm_group_label>Cohort A2: SAR444245 + pembrolizumab</arm_group_label>
    <arm_group_label>Cohort A3: SAR444245 + pembrolizumab + pemetrexed + carboplatin/cisplatin</arm_group_label>
    <arm_group_label>Cohort B1: SAR444245 + pembrolizumab</arm_group_label>
    <arm_group_label>Cohort B2: patients with NSCLC, to receive SAR444245+pembrolizumab+nab paclitaxel as 2/3L therapy</arm_group_label>
    <arm_group_label>Cohort C1: SAR444245 + pembrolizumab</arm_group_label>
    <other_name>THOR-707</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pharmaceutical Form: Solution for infusion Route of Administration: intravenous infusion</description>
    <arm_group_label>Cohort A1: SAR444245 + pembrolizumab</arm_group_label>
    <arm_group_label>Cohort A2: SAR444245 + pembrolizumab</arm_group_label>
    <arm_group_label>Cohort A3: SAR444245 + pembrolizumab + pemetrexed + carboplatin/cisplatin</arm_group_label>
    <arm_group_label>Cohort B1: SAR444245 + pembrolizumab</arm_group_label>
    <arm_group_label>Cohort B2: patients with NSCLC, to receive SAR444245+pembrolizumab+nab paclitaxel as 2/3L therapy</arm_group_label>
    <arm_group_label>Cohort C1: SAR444245 + pembrolizumab</arm_group_label>
    <other_name>Keytruda® or generic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Pharmaceutical Form: Solution for infusion Route of Administration: intravenous infusion</description>
    <arm_group_label>Cohort A3: SAR444245 + pembrolizumab + pemetrexed + carboplatin/cisplatin</arm_group_label>
    <other_name>Novaplus® or generic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Pharmaceutical Form: Solution for infusion Route of Administration: intravenous infusion</description>
    <arm_group_label>Cohort A3: SAR444245 + pembrolizumab + pemetrexed + carboplatin/cisplatin</arm_group_label>
    <other_name>Platinol-AQ® or generic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Pharmaceutical Form: powder for solution for infusion Route of Administration: intravenous infusion</description>
    <arm_group_label>Cohort B2: patients with NSCLC, to receive SAR444245+pembrolizumab+nab paclitaxel as 2/3L therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pharmaceutical Form: powder for solution for infusion Route of Administration: intravenous infusion</description>
    <arm_group_label>Cohort A3: SAR444245 + pembrolizumab + pemetrexed + carboplatin/cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be ≥18 years of age (or country's legal age of majority if &gt;18&#xD;
             years), at the time of signing the informed consent.&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of Stage IV NSCLC (cohorts A1, A2,&#xD;
             B1, B2), Stage IV non-squamous NSCLC (cohort A3), or unresectable malignant pleural&#xD;
             mesothelioma (cohort C1).&#xD;
&#xD;
          -  Cohort A1: PD-L1 expression TPS &gt; 50%&#xD;
&#xD;
          -  Cohort A2: PD-L1 expression TPS 1 - 49%&#xD;
&#xD;
          -  Prior anticancer therapy&#xD;
&#xD;
          -  Cohorts A1, A2, A3: No prior systemic therapy for advanced/metastatic NSCLC.&#xD;
             Participants who received adjuvant or neoadjuvant therapy are eligible if the&#xD;
             adjuvant/neoadjuvant therapy was completed at least 6 months prior to the development&#xD;
             of metastatic disease.&#xD;
&#xD;
          -  Cohorts B1, B2: One prior anti-PD1/PD-L1 regimen (may include chemotherapy) plus one&#xD;
             additional chemotherapy regimen&#xD;
&#xD;
          -  Cohort C1: One or two prior systemic treatments that include pemetrexed-based regimen&#xD;
             in combination with platinum agent.&#xD;
&#xD;
          -  All cohorts must have a measurable disease&#xD;
&#xD;
          -  Mandatory baseline biopsy for the first 20 participants to enroll in cohorts A1, A2&#xD;
&#xD;
          -  Cohorts B1 and B2: Based on the Investigator's judgment, either docetaxel or&#xD;
             pemetrexed is not the best treatment option for the participant.&#xD;
&#xD;
          -  Females are eligible to participate if they are not pregnant or breastfeeding, not a&#xD;
             woman of childbearing potential (WOCBP) or are a WOCBP that agrees:&#xD;
&#xD;
        to use approved contraception method and submit to regular pregnancy testing prior to&#xD;
        treatment and for 180 days after discontinuing study treatment to refrain from donating or&#xD;
        cryopreserving eggs for 180 days after discontinuing study treatment.&#xD;
&#xD;
          -  Males are eligible to participate if they agree to refrain from donating or&#xD;
             cryopreserving sperm, and either abstain from heterosexual intercourse OR use approved&#xD;
             contraception during study treatment and for at least 210 days after discontinuing&#xD;
             study treatment.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≥2.&#xD;
&#xD;
          -  Poor bone marrow reserve&#xD;
&#xD;
          -  Poor organ function&#xD;
&#xD;
          -  Participants with baseline SpO2 ≤92%.&#xD;
&#xD;
          -  Active brain metastases or leptomeningeal disease.&#xD;
&#xD;
          -  History of allogenic or solid organ transplant&#xD;
&#xD;
          -  Last administration of prior antitumor therapy or any investigational treatment within&#xD;
             28 days or less than 5 times the half-life, whichever is shorter; major surgery or&#xD;
             local intervention within 28 days.&#xD;
&#xD;
          -  Has received prior IL-2-based anticancer treatment.&#xD;
&#xD;
          -  Comorbidity requiring corticosteroid therapy&#xD;
&#xD;
          -  Antibiotic use (excluding topical antibiotics) ≤14 days prior to first dose of IMP&#xD;
&#xD;
          -  Severe or unstable cardiac condition within 6 months prior to starting study treatment&#xD;
&#xD;
          -  Active, known, or suspected autoimmune disease that has required systemic treatment in&#xD;
             the past 2 years&#xD;
&#xD;
          -  Known second malignancy either progressing or requiring active treatment within the&#xD;
             last 3 years&#xD;
&#xD;
          -  Cohorts A1, A2, A3, C1: Prior treatment with an agent (approved or investigational)&#xD;
             that blocks the PD1/PD-L1 pathway (participants who joined a study with an&#xD;
             anti-PD1/PD-L1 but have written confirmation they were on control arm are allowed).&#xD;
&#xD;
          -  Receipt of a live-virus vaccination within 28 days of planned treatment start.&#xD;
             Seasonal flu vaccines that do not contain live virus are permitted.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :0360001</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0360002</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3800001</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920004</name>
      <address>
        <city>Matsuyama-shi</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920001</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920002</name>
      <address>
        <city>Ube-shi</city>
        <state>Yamaguchi</state>
        <zip>755-0241</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400001</name>
      <address>
        <city>Hato Rey</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>October 26, 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

